Search Results - "Plander, M."
-
1
Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles
Published in Leukemia (01-11-2009)“…Chronic lymphocytic leukemia (CLL) is a malignancy of mature B-lymphocytes that manifests in a variety of clinical courses. The accumulation of CLL-cells is…”
Get full text
Journal Article -
2
THE EFFECT OF AN IMMUNOMODULATORY DRUG ON THE VIABILITY AND SURFACE MOLECULE EXPRESSION OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
Published in Hematological oncology (01-06-2017)Get full text
Journal Article -
3
Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation
Published in Cell proliferation (01-08-2007)“… Objectives: The potential of epidermal growth factor receptor (EGFR)‐ and Her2‐targeted antibodies Cetuximab, Pertuzumab and Trastuzumab, used in…”
Get full text
Journal Article -
4
P615: BCL2 RESISTANCE MUTATIONS IN A REAL‐WORLD COHORT OF PATIENTS WITH VENETOCLAX‐TREATED CHRONIC LYMPHOCYTIC LEUKAEMIA
Published in HemaSphere (23-06-2022)Get full text
Journal Article -
5
-
6
Optimization of three‐ and four‐color multiparameter DNA analysis in lymphoma specimens
Published in Cytometry. Part A (01-07-2003)“…Background Simultaneous analysis of DNA and immunophenotype of lymphoma cells by flow cytometry allows the calculation of the proliferative activity and…”
Get full text
Journal Article -
7
O44 Characterization of the proliferating chronic lymphocytic leukemia cells in an in vitro model for pseudofollicles
Published in Blood reviews (2007)Get full text
Journal Article -
8
Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma
Published in Journal of internal medicine (01-09-2023)“…Background Recent genomic studies revealed enhancer of zeste homolog 2 (EZH2) gain‐of‐function mutations, representing novel therapeutic targets in follicular…”
Get full text
Journal Article -
9
Screening and monitoring of the BTKC481S mutation in a real‐world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy
Published in British journal of haematology (01-07-2021)“…Summary The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has revolutionised the therapeutic landscape of chronic lymphocytic leukaemia (CLL). Acquired…”
Get full text
Journal Article -
10
Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax
Published in International journal of molecular sciences (18-03-2023)“…The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the…”
Get full text
Journal Article -
11
Lenalidomide abrogates the survival effect of bone marrow stromal cells in chronic lymphocytic leukemia
Published in Hematological oncology (01-10-2021)“…In the pathogenesis of chronic lymphocytic leukemia (CLL) the microenvironment plays an important role, as it produces survival signals and mediates drug…”
Get full text
Journal Article -
12
Cellular immune response in Dupuytren's disease
Published in Biochemia medica (2008)“…Background: The pathogenesis of Dupuytren's disease is unclear, but inflammatory mechanisms might be supposed in the background. Materials and methods: The…”
Get full text
Journal Article